Cargando…
In Response to: ‘Impact of Glycosylation on Effector Functions of Therapeutic IgG’ (Pharmaceuticals 2010, 3, 146–157)
To complete the review article by Abes and colleagues (Pharmaceuticals 2010, 3, 146–157) which provides a good overview on recently developed approaches for generation of glyco-modified antibodies and the impact of glyco-modification of antibodies on their effector functions, important information s...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033957/ https://www.ncbi.nlm.nih.gov/pubmed/27713333 http://dx.doi.org/10.3390/ph3061887 |
_version_ | 1782317904127066112 |
---|---|
author | Nechansky, Andreas Koller, Iris Kircheis, Ralf |
author_facet | Nechansky, Andreas Koller, Iris Kircheis, Ralf |
author_sort | Nechansky, Andreas |
collection | PubMed |
description | To complete the review article by Abes and colleagues (Pharmaceuticals 2010, 3, 146–157) which provides a good overview on recently developed approaches for generation of glyco-modified antibodies and the impact of glyco-modification of antibodies on their effector functions, important information should be added, namely that — besides the Glycart and the Biowa approach to generate de-fucosylated antibodies — innovative, moss derived methods have been shown to generate glyco-modified antibodies with improved effector function profile. |
format | Online Article Text |
id | pubmed-4033957 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-40339572014-05-27 In Response to: ‘Impact of Glycosylation on Effector Functions of Therapeutic IgG’ (Pharmaceuticals 2010, 3, 146–157) Nechansky, Andreas Koller, Iris Kircheis, Ralf Pharmaceuticals (Basel) Commentary To complete the review article by Abes and colleagues (Pharmaceuticals 2010, 3, 146–157) which provides a good overview on recently developed approaches for generation of glyco-modified antibodies and the impact of glyco-modification of antibodies on their effector functions, important information should be added, namely that — besides the Glycart and the Biowa approach to generate de-fucosylated antibodies — innovative, moss derived methods have been shown to generate glyco-modified antibodies with improved effector function profile. MDPI 2010-06-10 /pmc/articles/PMC4033957/ /pubmed/27713333 http://dx.doi.org/10.3390/ph3061887 Text en © 2010 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an Open Access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Commentary Nechansky, Andreas Koller, Iris Kircheis, Ralf In Response to: ‘Impact of Glycosylation on Effector Functions of Therapeutic IgG’ (Pharmaceuticals 2010, 3, 146–157) |
title | In Response to: ‘Impact of Glycosylation on Effector Functions of Therapeutic IgG’ (Pharmaceuticals 2010, 3, 146–157) |
title_full | In Response to: ‘Impact of Glycosylation on Effector Functions of Therapeutic IgG’ (Pharmaceuticals 2010, 3, 146–157) |
title_fullStr | In Response to: ‘Impact of Glycosylation on Effector Functions of Therapeutic IgG’ (Pharmaceuticals 2010, 3, 146–157) |
title_full_unstemmed | In Response to: ‘Impact of Glycosylation on Effector Functions of Therapeutic IgG’ (Pharmaceuticals 2010, 3, 146–157) |
title_short | In Response to: ‘Impact of Glycosylation on Effector Functions of Therapeutic IgG’ (Pharmaceuticals 2010, 3, 146–157) |
title_sort | in response to: ‘impact of glycosylation on effector functions of therapeutic igg’ (pharmaceuticals 2010, 3, 146–157) |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033957/ https://www.ncbi.nlm.nih.gov/pubmed/27713333 http://dx.doi.org/10.3390/ph3061887 |
work_keys_str_mv | AT nechanskyandreas inresponsetoimpactofglycosylationoneffectorfunctionsoftherapeuticiggpharmaceuticals20103146157 AT kolleriris inresponsetoimpactofglycosylationoneffectorfunctionsoftherapeuticiggpharmaceuticals20103146157 AT kircheisralf inresponsetoimpactofglycosylationoneffectorfunctionsoftherapeuticiggpharmaceuticals20103146157 |